⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Incyte da a conocer los datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de la crema Opzelura ® (ruxolitinib) en adultos con dermatitis atópica moderada
businesswire.com
INCY
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
businesswire.com
INCY
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
globenewswire.com
ADAG
ABBV
BIIB
BMRN
BLRX
CNSP
CYCN
GEN
GILD
GRAF
GSK
HSIC
HUBS
IBIO
INCY
JAZZ
JNJ
MAGN
MARA
MRK
NVS
OMER
PFE
PRGS
REGN
RGNX
SRPT
TENB
TGLS
TGTX
TNDM
TXG
VRTX
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
prnewswire.com
INCY
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
businesswire.com
INCY
Form 8-K
sec.gov
VRTX
INCY
Incyte to Present at Upcoming Investor Conferences
businesswire.com
INCY
Form 8-K
sec.gov
INCY
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
businesswire.com
INCY
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL